Electrilab Genetic Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-06-2024
- Paid Up Capital ₹ 0.10 M
as on 01-06-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2021
- Revenue 13.51%
(FY 2019)
- Profit 26.24%
(FY 2019)
- Ebitda 350.89%
(FY 2019)
- Net Worth 28.14%
(FY 2019)
- Total Assets 0.16%
(FY 2019)
About Electrilab Genetic
The Corporate was formerly known as Electrichem Gravures Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Alok Gupta and Renu Gupta serve as directors at the Company.
- CIN/LLPIN
U27209RJ2013PTC042913
- Company No.
042913
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 2013
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Electrilab Genetic Private Limited offer?
Electrilab Genetic Private Limited offers a wide range of products and services, including IVDs & Analyzers, Hematology Analyzers, Clinical Reagents, Hematology Reagents, Cell Counter, Medical Laboratory Instruments, Biochemistry Analyzer.
Who are the key members and board of directors at Electrilab Genetic?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alok Gupta  | Director | 12-Jun-2013 | Current |
| Renu Gupta | Additional Director | 28-Jun-2019 | Current |
Financial Performance of Electrilab Genetic.
Electrilab Genetic Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 13.51% increase. The company also saw a substantial improvement in profitability, with a 26.24% increase in profit. The company's net worth Soared by an impressive increase of 28.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Electrilab Genetic?
In 2017, Electrilab Genetic had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Electrilab Genetic?
Unlock and access historical data on people associated with Electrilab Genetic, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Electrilab Genetic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Electrilab Genetic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
